XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2
Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2018
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Loss Contingencies [Line Items]          
Operating leases, rent expense   $ 47,000 $ 72,000 $ 100,000 $ 100,000
Remaining lease term   6 months   6 months  
Incremental borrowing rate used to determine operating lease liability percentage       4.25%  
Teva Agreement          
Loss Contingencies [Line Items]          
Payment upon achievement of certain clinical and commercial milestones $ 135,000,000.0        
Asset transfer and license agreement, termination period after written notice       120 days  
Asset transfer and license agreement, termination period notice of breach       60 days  
Asset transfer and license agreement termination notice period if bankruptcy petition filed       60 days  
Teva Agreement | Research and Development Expenses          
Loss Contingencies [Line Items]          
Milestone payments   $ 0 $ 0 $ 0 $ 0
Teva Agreement | Teva's GlycoPEGylated FGF21 Program          
Loss Contingencies [Line Items]          
Payment upon achievement of certain clinical and commercial milestones 67,500,000        
Teva Agreement | Teva's Development Program          
Loss Contingencies [Line Items]          
Payment upon achievement of certain clinical and commercial milestones $ 67,500,000